We outline the new information to take into account as companies draft PVP disclosures, and note which issues remain open for imminent filers.

Despite a slowing economy and increased prevalence of job cuts, the market for talent in life sciences remains strong, as does wage inflation.

A decline in share prices creates challenges in the current equity grant cycle. Our data show how biotech companies are making adjustments.

New data on director compensation and board composition point to a year-over-year decrease in TDC and two emerging trends.

Survey results from 58 public and private bank institutions outlining their expectations for executive compensation programs in 2023.

As human capital issues become an increasing area of responsibility, working relationships with management and advisors may evolve.

The data point to clear trends in base salaries, use of incentive pay, and bonuses.

As individual affordable housing organizations struggle, there is a benefit to understanding compensation levels and trends in the broader industry.

As a merger, acquisition, or sale takes shape, whether and how much to pay for bonuses is a key decision point for compensation committees.

Updated policy guidelines from ISS and Glass Lewis include compensation- and director-related items that should be reviewed for 2023.

What can be done to alleviate the burnout and help healthcare organizations attract, motivate, and retain employees?

These responsibilities may not have the same level of focus on private boards, compared to public. Here’s how visionary private boards can take action.